The psoriasis treatment guideline of the American Academy of Dermatology mentions that IBs (anti-TNF, anti-IL12/23, anti-IL17 and anti-IL23) can be used in patients with HIV infection, provided they are receiving ART, have normal CD4, undetectable viral load and do not have recent OIs. This evidence concerns the gene IL37 and HIV infectious disease.